A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
Latest Information Update: 12 Apr 2024
At a glance
- Drugs Octreotide (Primary) ; Lanreotide; Octreotide
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms SORENTO
- Sponsors Camurus
- 25 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Jan 2024 Trial design published in the Trials
- 07 Jun 2022 Trial design, presented at the 58th Annual Meeting of the American Society of Clinical Oncology